|
|
Post by peppy on Feb 17, 2023 16:12:50 GMT -5
This is reminding me of an old fashion share price earnings run up. MNKD Nasdaq real time volume, 3,059,013 shares. MNKD Nasdaq summary volume, 3,024,342 Avg. Volume 3,800,986 $5.63. +0.26 (+4.84%) MNKD Charts daily, schrts.co/xWcsWxiQ. The daily looks good. All lines pointing up. Weekly, schrts.co/yNdsyCMj. The weekly, price coming out of the two year consolidation, all lines pointing up. Point of triangle break out the larger more powerful faster break out price movement just above. Monthly. schrts.co/AubVFdiA. This price chart picture is perfect. $5.90, $12.00 and then we continue, when we continue, share price will climb that wedge, look left..  That is what I am thinking, that is all I have. Ridem |
|
|
|
Post by peppy on Feb 17, 2023 15:37:55 GMT -5
Sorry if this is the wrong thread, or if it has been answered already… How long does MNKD need to stay above $5.00 to be added back into relevant index funds? Would such an event add volume and potential price gains? Thanks in advance for any info! scroll down as well. IBB holds 11 million shares. |
|
|
|
Post by peppy on Feb 17, 2023 13:38:04 GMT -5
$5.61. +0.24 (+4.38%)
As of 01:36PM EST. Market open.
New 52 week high on the day.
1,567,171
Avg. Volume 3,800,986
|
|
|
|
Post by peppy on Feb 17, 2023 12:45:39 GMT -5
www.wsj.com/market-data/stocks/newfiftytwoweekhighsandlowsMNKD listed on the Wall Street journal Nasdaq new 52 week highs, the high listed as todays high of $5.60. It turns out these charts I post refresh, Look at the monthly, the 100 month sitting on MNKD price, like a hat on a head, Look left, $5,59 and then $6,25. The resistance points price is working through. MNKD Monthly schrts.co/vsXBenPbMNKD volume at the half day trade, real time, 1,211,397 shares. summary, 1,211,697 $5.51. +0.14 (+2.70%)
|
|
|
|
Post by peppy on Feb 17, 2023 11:01:22 GMT -5
Thanks. It has been such a long journey. This time I think the price rise should be on a solid foundation. We know UTHR has solid news on Tyvaso DPI. Hopefully Mike has other good news and we should see some ABC results. and harryx1 charts are posted. Thank you kippyt The trajectory is up. The trajectory for share price is a quick double and then we see. That is my story and I am sticking to it. With pictures, lines, circles and arrows. MNKD testing and back up now. 5.51+0.14 (+2.70%) As of 11:12AM EST. Market open. on 1,017,436 Avg. Volume 3,800,986 |
|
|
|
Post by peppy on Feb 17, 2023 10:47:40 GMT -5
Why did it spike 2 years ago? Wasn't it part of the continuing upward trend surrounding the agreement with United over Tyvaso? Positive Breeze study results were releases in January 2021. Causing the price to spike to 6. Then Mannkind issued some notes March 1st followed by an increase of those notes to 200 million. That tanked the price. Even though this restructuring of debt under those low interest periods looks great now, it was probably used to short the hell out of the stock. agreed Celo. also 60 days later, investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-proposed-private-placement |
|
|
|
Post by peppy on Feb 17, 2023 10:29:34 GMT -5
Highest share price in 2 years. Look out there isn't much resistance to 6. Lovely! Why did it spike 2 years ago? financing.... the last round, the convertibles at $5,21. |
|
|
|
Post by peppy on Feb 17, 2023 10:13:48 GMT -5
BAM, MNKD makes a new 52 week high...... The nasdaq is at 11748......
5.53+0.16 (+2.89%)
As of 10:12AM EST. Market open.
BAM BAM
571,068
Avg. Volume 3,800,986
At one hour of trade, volume,
realtime, 800,
summary, 802,028
Avg. Volume 3,800,986
5.53+0.16 (+3.07%)
As of 10:30AM EST. Market open.
$5.60 hit.
|
|
|
|
Post by peppy on Feb 17, 2023 10:01:04 GMT -5
MNKD volume at 30 mins of trade on this options expiry.
real time, 331,424
summary,337,170
Avg. Volume 3,800,986
5.45. +0.08 (. +1.49%)
As of 10:00AM EST. Market open.
5.47+0.10 (+1.77%)
As of 10:00AM EST. Market open.
$5.52 will be a new 52 week high over $5 to show up on the new 52 week high lists.
|
|
|
|
Post by peppy on Feb 16, 2023 17:25:30 GMT -5
2022 call Thursday 23rd @ 5:00 Estern UTHR United Therapeutics Corporation to Report Fourth Quarter and Full Year 2022 Financial Results Before the Market Opens on Wednesday, February 22, 2023MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 202302/16/23 will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Thursday, February 23, 2023. Thank you. |
|
|
|
Post by peppy on Feb 16, 2023 16:06:43 GMT -5
MNKD Nasdaq real time volume, real time, 1,508,791 shares. summary, 1,915,775 Avg. Volume 3,822,334 $5.37. +0.01. (+0.19%) Nasdaq - 11,855.83 -214.76(-1.78%) MNKD weekly schrts.co/sHcHbKbX$COMPQ weekly. schrts.co/tXbUtYpksecond inside week. |
|
|
|
Post by peppy on Feb 16, 2023 14:23:03 GMT -5
Its pretty exciting what Novo's are up to. the trial for Idcodec "onwards 6" involved Icodec + injectable RAA. I don't have the exact specifics but patients were found to be at higher risk of experiencing lows which gave Novo some negative press when they released the results. Now im no doctor but i wonder if the lows were a result of "stacking" due to the long duration of the RAA, if however they used afrezza for the meal time control my assumption would be that the likelihood of lows would be greatly reduced because of the "fast out" nature of afrezza. Novo are now bigger that LLY in mkt cap. culture wise i see MNKD working better with NOVOB than LLY. IMO So you raise a good point - additional severe hypos which are nearly doubled. That IMO is a show stopper. In the trial, there was a statistically significant higher estimated rate of severe or clinically significant hypoglycaemia (blood glucose below 3 mmol/L) with 19.93 events per patient year exposed to once-weekly insulin icodec and 10.37 events per patient-year exposed to insulin degludec. From Mike's comments he said MNKD is very excited about the use of afrezza with icodec. Did MNKD just do a pilot on their own or did they work with NVO on this? I would think doubling severe hypo's makes this a non-starter for most endo's and even more so for GPs. What the primary target is for icodec I am not sure. I can see a real benefit for the T2s who are going to put on a basal. However, adding the prandial points us more toward the T1s. As Aged said, would NVO consider having afrezza compete against Novolog and Fiasp? I guess I could argue Fiasp has not lived up to the expectations NVO had for it. Would NVO be OK with afrezza taking some of the Novolog business? They were with Fiasp. UTHR was ok with Tyvaso DPI. I guess if they see afrezza more than the "niche" drug and has the potential many of us believe maybe they would be more than OK. One thing for sure is Mike said MNKD has a partner for the Big pump study and if the partner if NVO, that would be a really big deal. We do know Tresiba was the basal used during the ABC Pilot. We also know Mike said some info would be released at ATTD 2023 which is 22-25 February 2023. Will they announce the partner for the "BIG" study then, maybe. Peppy - what do you think. Would a NVO partnership pop the stock over $6 or more? haha. you know it would. |
|
|
|
Post by peppy on Feb 16, 2023 12:48:31 GMT -5
MNKD volume at the half day of trade, 576,231 shares. $5.43. +0.07 (+1.21%) schrts.co/NFSEAcUB |
|
|
|
Post by peppy on Feb 16, 2023 12:36:35 GMT -5
Expected Earnings 4th Quarter Earnings Announcement Expected: Earnings will tentatively be announced 02/23/2023 before market open. With 5 analysts covering MNKD, the consensus EPS estimate is -$0.06, and the high and low estimates are -$0.05 and -$0.08, respectively. Year Over Year Growth: For the fourth quarter 2022, analysts estimate MNKD will earn -$0.06 non-GAAP per share, an increase of 43.64% over the prior year fourth quarter non-GAAP results. The PR needs to come out today for a CC on the 23rd? |
|
|
|
Post by peppy on Feb 16, 2023 10:01:16 GMT -5
MNKD volume at 30 mins of trade. real time, 182,772 summary. 183,982 Avg. Volume 3,822,334 $5.39. +0.03 (+0.65%) when MNKD reaches $5.52 it will show up on the new 52 week high list over $5. MNKD volume at 1 hour of trade, real time, 264,643 summary, 265,962 5.42+0.06 (+1.12%) finance.yahoo.com/quote/MNKD?p=MNKD |
|
